Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients

Objectives: To evaluate the ability for pre-treatment NLR and MLR to predict overall survival (OS) and modified Rankin Scale (mRS) and to explore their relationship with clinicopathological parameters. Methods: Retrospective analysis of pretreatment NLR and MLR from 64 glioma patients. Results: Higher pretreatment NLR (>4.7) predicted higher mean admission mRS (p < 0.001) and 6-month mRS (p = 0.02). Higher pretreatment MLR (>0.35) was a risk factor for poorer OS in glioma patients (p = 0.024). Higher pretreatment NLR was significantly associated with larger tumor diameter (p = 0.02). Conclusion: NLR and MLR can serve as prognostic markers to predict functional outcomes and OS in glioma patients

Automated summary

The study findings suggest that pre-treatment NLR and MLR are associated with survival and functional outcomes in glioma patients. Higher NLR and MLR values are correlated with poorer prognosis.